Murdoch University Research Repository

Welcome to the Murdoch University Research Repository

The Murdoch University Research Repository is an open access digital collection of research
created by Murdoch University staff, researchers and postgraduate students.

Learn more

HLA-B*5701 Taqman assay for abacavir sensitivity: Application to PREDICT-1 trial

Bugawan, T., Isoda, W., Mallal, S., Thorborn, D. and Erlich, H. (2008) HLA-B*5701 Taqman assay for abacavir sensitivity: Application to PREDICT-1 trial. In: 34th Annual Meeting of the American Society for Histocompatibility and Immunogenetics (ASHI) 2008, 27 - 31 October 2008, Toronto, Canada.


Aim: Around 5% of HIV infected patients treated with the HIV drug abacavir experience an allergic hypersensitive response within 6 weeks. Genetic association studies have shown that the HLA-B*5701 allele is highly associated with abacavir hypersensitivity (Mallal et al 2002). and studies of in vitro T cell responses to abacavir pulsed APC indicate that the B*5701 allele is a causal determinant of allergic hypersensitivity (Chessman et al 2007). Our aim was to develop a real-time PCR method of detecting the B*5701 allele on the same automated platform (Cobas AmpliPrep/Cobas TaqMan;CAP/CTM) currently used for determining HIV viral load.

Methods: The B*5701 CTM is a single tube, 2 channel research assay using 2 pairs of primers and Hex- and Fam-labeled Taqman probes. A Hex labeled control probe binds to the exon 2 of all HLA-B alleles. The exon 3 primers and the Fam labeled probe are B*5701 specific.

Results: This assay was used to determine the B*5701 status of 1956 DNA samples from the PREDICT-1 study (Mallal et al 2008). This study demonstrated the clinical utility of B*5701 screening prior to abacavir treatment. HLA-B*5701 status was independently determined by using SSOP followed by SBT for HLA-B57 positive samples (LabCorp) as well as SBT single step full allelic typing (Perth). The Roche CTM HLA-B*5701 results are fully concordant with the sequencing results. Currently, this research assay can be run on whole blood in the same integrated CAP/CTM platform used for measuring HIV viral load.

Conclusions: The HLA-B*5701 CAP/CTM assay is a valuable research screening test for determining HLA-B*5701 status in abacavir-naï ve HIV patients.

Item Type: Conference Item
Murdoch Affiliation(s): Centre for Clinical Immunology and Biomedical Statistics
Conference Website:
Item Control Page Item Control Page